Henan Lingrui Pharmaceutical Co., Ltd. (SHA:600285)
China · Delayed Price · Currency is CNY 23.87
+0.30 (1.27%)
Nov 6, 2026, 3:00 PM CST
SHA:600285 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 13,537 | 11,663 | 12,480 | 9,649 | 7,358 | 8,920 | |
Market Cap Growth | 8.33% | -6.54% | 29.34% | 31.14% | -17.51% | 85.47% |
Enterprise Value | 12,877 | 10,864 | 11,552 | 8,482 | 6,324 | 8,108 |
Last Close Price | 23.87 | 19.67 | 20.26 | 15.14 | 11.11 | 12.94 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.36 | 15.36 | 17.27 | 16.98 | 15.81 | 24.67 |
Forward PE | 16.34 | 13.59 | 16.50 | 16.45 | 14.45 | 20.52 |
PS Ratio | 3.43 | 3.03 | 3.57 | 2.91 | 2.45 | 3.31 |
PB Ratio | 3.87 | 3.39 | 4.05 | 3.45 | 2.88 | 3.90 |
P/TBV Ratio | 5.12 | 4.51 | 4.35 | 3.73 | 3.14 | 4.37 |
P/FCF Ratio | 13.21 | 23.47 | 16.40 | 12.18 | 9.11 | 11.60 |
P/OCF Ratio | 12.48 | 21.06 | 14.25 | 11.86 | 8.81 | 10.55 |
PEG Ratio | - | 0.80 | 0.87 | 0.37 | 0.37 | 0.37 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.26 | 2.82 | 3.30 | 2.56 | 2.11 | 3.01 |
EV/EBITDA Ratio | 12.56 | 11.81 | 14.52 | 12.76 | 13.65 | 18.11 |
EV/EBIT Ratio | 14.22 | 13.18 | 15.96 | 14.40 | 16.25 | 21.54 |
EV/FCF Ratio | 12.56 | 21.86 | 15.19 | 10.71 | 7.83 | 10.55 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.12 | 0.03 | 0.07 | 0.06 | 0.12 |
Debt / EBITDA Ratio | 0.31 | 0.45 | 0.12 | 0.31 | 0.34 | 0.63 |
Debt / FCF Ratio | 0.31 | 0.84 | 0.13 | 0.26 | 0.20 | 0.37 |
Net Debt / Equity Ratio | -0.20 | -0.20 | -0.46 | -0.49 | -0.51 | -0.41 |
Net Debt / EBITDA Ratio | -0.69 | -0.73 | -1.78 | -2.09 | -2.80 | -2.10 |
Net Debt / FCF Ratio | -0.68 | -1.36 | -1.86 | -1.75 | -1.60 | -1.22 |
Asset Turnover | 0.66 | 0.72 | 0.72 | 0.73 | 0.74 | 0.74 |
Inventory Turnover | 2.22 | 1.77 | 1.88 | 1.86 | 1.83 | 1.86 |
Quick Ratio | 0.78 | 0.86 | 1.07 | 1.11 | 1.16 | 1.16 |
Current Ratio | 1.23 | 1.08 | 1.31 | 1.37 | 1.47 | 1.48 |
Return on Equity (ROE) | 24.55% | 23.40% | 24.58% | 21.21% | 19.21% | 15.73% |
Return on Assets (ROA) | 9.49% | 9.67% | 9.24% | 8.08% | 5.98% | 6.49% |
Return on Invested Capital (ROIC) | 31.87% | 32.27% | 41.04% | 38.32% | 26.85% | 21.97% |
Return on Capital Employed (ROCE) | 25.30% | 23.40% | 23.00% | 20.50% | 14.80% | 16.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.11% | 6.51% | 5.79% | 5.89% | 6.32% | 4.05% |
FCF Yield | 7.57% | 4.26% | 6.10% | 8.21% | 10.98% | 8.62% |
Dividend Yield | 4.61% | 5.34% | 4.07% | 4.68% | 4.64% | 3.16% |
Payout Ratio | 75.53% | 67.32% | 62.47% | 60.60% | 62.08% | 61.91% |
Buyback Yield / Dilution | 0.53% | -0.64% | 0.42% | 0.30% | -0.26% | 0.24% |
Total Shareholder Return | 5.14% | 4.70% | 4.49% | 4.98% | 4.39% | 3.40% |